The patient was diagnosed with MOGAD after receiving an mRNA SARS-CoV-2 vaccination.
MOG AUTOIMMUNE SKIN
Tests for soluble interleukin (IL)-2 receptors in the serum, IL-6 in the CSF and skin pricks, and angiotensin converting enzyme tests were all unremarkable. The patient's serum test results for cytoplasmic-antineutrophil cytoplasmic antibodies, perinuclear-cytoplasmic-antineutrophil cytoplasmic antibodies, GQ1b-antibodies, and aquaporin-4 antibodies (AQP4-IgG) were all negative. Laboratory workups were positive for serum MOG-IgG as assessed by live cell-based assays and the presence of oligoclonal bands in the cerebrospinal fluid (CSF). Other neurological examinations were unremarkable. A neurological examination revealed paresthesia on her right V2 and V3 areas. The patient's brain MRI revealed a right cerebellar peduncle lesion with gadolinium enhancement, a typical finding of MOGAD. A previously healthy 68-year-old woman presented to our department with gradually worsening numbness on the right side of her face, which began 14 days after her second dose of an mRNA-1273 vaccination. Here we report a case of MOGAD after mRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disorder (MOGAD) is a newly identified autoimmune demyelinating disorder that is often associated with acute disseminated encephalomyelitis and usually occurs postinfection or postvaccination. 3Department of Neurology, National Hospital Organization Yonezawa Hospital, Yonezawa, Japan.2Department of Neurology, Tohoku University Hospital, Sendai, Japan.1Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan.Yuki Matsumoto 1 Ayane Ohyama 2 Takafumi Kubota 2 Kensuke Ikeda 2 Kimihiko Kaneko 2 Yoshiki Takai 2 Hitoshi Warita 2 Toshiyuki Takahashi 3 Tatsuro Misu 2 * Masashi Aoki 1,2
0 kommentar(er)
